GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

KeyBanc upgraded Generac (GNRC) to Overweight with a $280 price target, citing confidence in its $8B Amazon deal. GNRC stock is up 62% YTD. Analysts debate capacity ramp-up, but management is confident. Other firms also raised targets, while some lowered them due to execution concerns.

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

Biohaven (BHVN) has licensed IgG degraders to Ono Pharma for Japan and select Asian regions. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. The agreement marks a strategic partnership and late-stage pipeline update for Biohaven's immunology platform.